Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:05:45.382Z.
Calculation as of: 2026-10-06T15:05:45.382Z.
Quote observation: 2026-10-06T15:05:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$665.40M
EV/EBITDA Ratio
26.02x
TTM Avg
12.95x
3Y Avg
19.43x
5Y Avg
199.83x
Market Cap
$665.48M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$609.24M
EV/EBITDA Ratio
N/A
TTM Avg
8.45x
3Y Avg
304.75x
5Y Avg
435.98x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $642.86M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $640.05M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $637.30M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $665.40M | 26.02x | 12.95x | 19.43x | 199.83x |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $665.48M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $609.24M | N/A | 8.45x | 304.75x | 435.98x |
| Helus Pharma Inc. (HELP)vs › | $671.29M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $622.01M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $682.40M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $601.74M | N/A | 2.62x | 44.68x | 68.34x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
